An Experimental Study on the Addition of Bacteria to Residual Anticancer Drugs : Evaluation of the Effect on Bacterial Growth
Using anticancer drugs as examples, we examined the possibility of reusing residual drugs. The use of residual drugs is not widespread owing to concerns regarding bacterial contamination. We combined anticancer drugs and bacteria to investigate their effects on bacterial growth. The anticancer drugs carboplatin, paclitaxel, etoposide, irinotecan, methotrexate, and 5-fluorouracil (5-FU) were mixed with Staphylococcus aureus, Enterococcus faecalis, Serratia marcescens, and Escherichia coli. After a certain period, the bacteria were counted. Irinotecan showed no antibacterial activity, whereas 5-FU exhibited high antibacterial activity against the tested bacteria. The 5-FU also showed a minimum inhibitory concentration value in the range of 8-80 μg/mL, depending on the bacterial species. 5-FU dose-dependently inhibited S. aureus growth at more than 0.8 µg/mL. Because protein synthesis systems are reportedly antibiotic targets, we used a cell-free protein synthesis system to confirm the mechanism of the antibacterial activity of the anticancer agent. 5-FU and methotrexate had direct inhibitory effects on protein synthesis. It has been suggested that even if residual drugs are contaminated with bacteria, there will be no microbial growth, or the microbes will be killed by the drug. With careful monitoring, 5-FU can potentially be used for antimicrobial purposes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:77 |
|---|---|
| Enthalten in: |
Japanese journal of infectious diseases - 77(2024), 2 vom: 21. März, Seite 61-67 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kikuchi, Ken [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 22.03.2024 Date Revised 22.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.7883/yoken.JJID.2023.270 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364061855 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364061855 | ||
| 003 | DE-627 | ||
| 005 | 20240323000251.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.7883/yoken.JJID.2023.270 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1341.xml |
| 035 | |a (DE-627)NLM364061855 | ||
| 035 | |a (NLM)37914291 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kikuchi, Ken |e verfasserin |4 aut | |
| 245 | 1 | 3 | |a An Experimental Study on the Addition of Bacteria to Residual Anticancer Drugs |b Evaluation of the Effect on Bacterial Growth |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.03.2024 | ||
| 500 | |a Date Revised 22.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Using anticancer drugs as examples, we examined the possibility of reusing residual drugs. The use of residual drugs is not widespread owing to concerns regarding bacterial contamination. We combined anticancer drugs and bacteria to investigate their effects on bacterial growth. The anticancer drugs carboplatin, paclitaxel, etoposide, irinotecan, methotrexate, and 5-fluorouracil (5-FU) were mixed with Staphylococcus aureus, Enterococcus faecalis, Serratia marcescens, and Escherichia coli. After a certain period, the bacteria were counted. Irinotecan showed no antibacterial activity, whereas 5-FU exhibited high antibacterial activity against the tested bacteria. The 5-FU also showed a minimum inhibitory concentration value in the range of 8-80 μg/mL, depending on the bacterial species. 5-FU dose-dependently inhibited S. aureus growth at more than 0.8 µg/mL. Because protein synthesis systems are reportedly antibiotic targets, we used a cell-free protein synthesis system to confirm the mechanism of the antibacterial activity of the anticancer agent. 5-FU and methotrexate had direct inhibitory effects on protein synthesis. It has been suggested that even if residual drugs are contaminated with bacteria, there will be no microbial growth, or the microbes will be killed by the drug. With careful monitoring, 5-FU can potentially be used for antimicrobial purposes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a antibacterial activity | |
| 650 | 4 | |a anticancer agents | |
| 650 | 4 | |a bacterial contamination | |
| 650 | 4 | |a residual medicine | |
| 650 | 7 | |a Methotrexate |2 NLM | |
| 650 | 7 | |a YL5FZ2Y5U1 |2 NLM | |
| 650 | 7 | |a Irinotecan |2 NLM | |
| 650 | 7 | |a 7673326042 |2 NLM | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Fluorouracil |2 NLM | |
| 650 | 7 | |a U3P01618RT |2 NLM | |
| 700 | 1 | |a Miyauchi, Rei |e verfasserin |4 aut | |
| 700 | 1 | |a Yamaguchi, Tomoya |e verfasserin |4 aut | |
| 700 | 1 | |a Sugiura, Hayato |e verfasserin |4 aut | |
| 700 | 1 | |a Nogami, Taishi |e verfasserin |4 aut | |
| 700 | 1 | |a Inoue, Yuki |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Haruna |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Hideki |e verfasserin |4 aut | |
| 700 | 1 | |a Fujiwara, Nagatoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Maeda, Shinji |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Japanese journal of infectious diseases |d 1999 |g 77(2024), 2 vom: 21. März, Seite 61-67 |w (DE-627)NLM104387572 |x 1884-2836 |7 nnns |
| 773 | 1 | 8 | |g volume:77 |g year:2024 |g number:2 |g day:21 |g month:03 |g pages:61-67 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.7883/yoken.JJID.2023.270 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 77 |j 2024 |e 2 |b 21 |c 03 |h 61-67 | ||